Literature DB >> 3120989

Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery.

L Poller1, A McKernan, J M Thomson, M Elstein, P J Hirsch, J B Jones.   

Abstract

A prospective study was carried out to see whether a small fixed dose of warfarin (1 mg daily) given before operation (mean 20 days) would prevent deep vein thrombosis in patients having major gynaecological surgery. One hundred and four patients were randomised into three groups: fixed minidose warfarin; full dose oral anticoagulation; and no treatment (controls). There was a significantly lower incidence of deep vein thrombosis in the minidose warfarin and full dose anticoagulant treatment groups (9% (3/32) and 3% (1/35) respectively) than in the controls (30%; 11/37) but no significant difference between the two anticoagulant treatment groups. Prothrombin time and the activated partial thromboplastin time were normal on the day of surgery in the warfarin treatment group, whereas times were prolonged in the group given full dose anticoagulation. Mean haemoglobin concentrations fell in all three groups after operation but the fall was significantly less in the minidose warfarin treatment group than after full dose anticoagulation. The benefit from full dose oral anticoagulant prophylaxis, based on a preoperative international normalised ratio of 1.5-2.5 with rabbit brain Manchester reagent, was similar to the protection achieved in an oral anticoagulant treatment group controlled with human brain Manchester comparative reagent at a similar level of anticoagulation. The lack of disturbance of normal haemostasis at the time of operation together with a significant reduction in deep vein thrombosis may encourage surgeons to introduce minidose prophylaxis with warfarin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120989      PMCID: PMC1248380          DOI: 10.1136/bmj.295.6609.1309

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  7 in total

1.  Prophylaxis against central vein thrombosis with low-dose warfarin.

Authors:  M M Bern; A Bothe; B Bistrian; C D Champagne; M S Keane; G L Blackburn
Journal:  Surgery       Date:  1986-02       Impact factor: 3.982

2.  Low-dose subcutaneous heparin versus oral anticoagulants in the prevention of postoperative deep-venous thrombosis. A controlled clinical trial.

Authors:  T J van Vroonhoven; J van Zijl; H Muller
Journal:  Lancet       Date:  1974-03-09       Impact factor: 79.321

3.  Low doses of subcutaneous heparin in the prevention of deep vein thrombosis after gynaecological surgery.

Authors:  R M Ballard; P J Bradley-Watson; F D Johnstone; A Kenney; T G McCarthy
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-05

4.  Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.

Authors:  P F Leyvraz; J Richard; F Bachmann; G Van Melle; J M Treyvaud; J J Livio; G Candardjis
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

5.  An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery.

Authors:  L Poller; D A Taberner; D G Sandilands; C S Galasko
Journal:  Thromb Haemost       Date:  1982-02-26       Impact factor: 5.249

6.  Dosage and control of oral anticoagulants: an international collaborative survey.

Authors:  L Poller; D A Taberner
Journal:  Br J Haematol       Date:  1982-07       Impact factor: 6.998

7.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Authors:  R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

  7 in total
  20 in total

1.  The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.

Authors:  J M Walenga; D Hoppensteadt; R Pifarré; N L Fox; S Forman; D B Hunninghake; L Campeau; J A Herd; B J Hoogwerf; A Hickey; J L Probstfield; M L Terrin
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 2.  Very low-intensity antithrombotic therapy in atrial fibrillation.

Authors:  B G Koefoed; P Petersen
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Therapeutic ranges for oral anticoagulation in different thromboembolic disorders.

Authors:  L Poller
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

4.  Prevention of venous thrombosis with minidose warfarin after joint replacement.

Authors:  C Dale; A Gallus; A Wycherley; S Langlois; D Howie
Journal:  BMJ       Date:  1991-07-27

Review 5.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

Review 6.  Unresolved issues in the prevention of venous thromboembolism.

Authors:  T Baglin
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 7.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

8.  Anticoagulation may be beneficial in high risk factor V Leiden carriers.

Authors:  T Baglin; C Baglin; K Brown; R Luddington
Journal:  BMJ       Date:  1998-08-08

9.  Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study.

Authors:  L Poller; P K MacCallum; J M Thomson; W Kerns
Journal:  Br Heart J       Date:  1990-04

10.  Efficacy of fixed minidose warfarin prophylaxis in total hip replacement.

Authors:  M J Fordyce; A S Baker; G E Staddon
Journal:  BMJ       Date:  1991-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.